Scheduled August 21, 2008 at 9:30 a.m.
SUNRISE, Fla., Aug. 1 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) today announced that Howard J. Leonhardt, Chairman and CEO of Bioheart, will present a corporate overview Thursday, August 21, 2008 at 9:30 a.m. ET during the Red Chip Investor Conference at the Marriott Marquis in New York. A live audio webcast and slide presentation will be available via the internet by visiting and registering to attend at: http://www.redchip.com.
ABOUT BIOHEART, INC.
Bioheart, Inc., (Nasdaq: BHRT) is committed to delivering intelligent
devices and biologics that help monitor, diagnose and treat heart failure
and cardiovascular diseases. Its goals are to improve a patient's quality
of life and reduce health care costs and hospitalizations. Specific to
biotechnology, Bioheart is focused on the discovery, development and,
subject to regulatory approval, commercialization of autologous cell
therapies for the treatment of chronic and acute heart damage. Its lead
product candidate, MyoCell(R), is an innovative clinical muscle-derived
stem cell therapy designed to populate regions of scar tissue within a
patient's heart with new living cells for the purpose of improving cardiac
function in chronic heart failure patients. The Company's pipeline includes
multiple product candidates for the treatment of heart damage, including
Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem
cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy
utilizing autologous cells that are genetically modified to express
additional potentially therapeutic growth proteins. For more information on
Bioheart, visit http://www.bioheartinc.com.
MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.
Contact: William Kline Lytham Partners, LLC
Chief Financial Officer Joe Diaz
Nicholas Burke Joe Dorame
VP - Financial Operations Robert Blum
(954) 835-1500 (602) 889-9700
|SOURCE Bioheart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved